бринсулмиди ч 40 ед/мл

бринсулмиди ч 40 ед/мл Medicine

Overdose

Symptoms: a sharp increase in sweating, tachycardia, tremor, hunger, agitation, paresthesia in the mouth, pallor of the skin, headache, in severe cases — hypoglycemic coma.

Treatment: ingestion of sugar or foods rich in carbohydrates, in severe cases, when the patient loses consciousness-the introduction of glucose (40% solution in/in) and glucagon (in/m).

Contraindications

Hypersensitivity, hypoglycemia.

Incompatibilities

MAO inhibitors, non-selective beta-blockers, sulfonamides, anabolic steroids, tetracyclines, clofibrate, cyclophosphamide, fenfluramine and drugs containing ethanol, enhance the hypoglycemic effect, oral contraceptives, glucocorticoids, thyroid hormones, thiazide diuretics, heparin, lithium preparations and tricyclic antidepressants — weaken. Reserpine and salicylates can both weaken and enhance the hypoglycemic effect.

Undesirable effects

Hypoglycemia, allergic reactions (skin rash, rarely-angioedema), hyperemia, itching, lipodystrophy (with prolonged use) at the injection site.

Special instructions

Patients receiving more than 100 units/day of Brinsulmidi H, when changing the drug, it is advisable to be hospitalized.

The transition from one type of insulin to another should be carried out under the control of blood glucose levels.

With the initial appointment, a change in the type of insulin or the occurrence of stressful situations during treatment, it is possible to reduce the ability to drive vehicles and mechanisms, to other potentially dangerous activities that require increased attention and speed of reaction.

With changes in the nature and diet, significant physical exertion, infectious diseases, surgical interventions, pregnancy, thyroid dysfunction, Addison's disease, hypopituitarism, renal failure, and in patients over 65 years of age, it is necessary to adjust the dose.

Insulin lowers the tolerance for alcohol.

If you need to take any medications, you should consult your doctor.

Therapeutic indications

Diabetes mellitus (type 1) in adults, diabetes mellitus (type 2) (in the case of resistance to oral hypoglycemic agents, including partial during combination therapy, against the background of intercurrent diseases, during pregnancy).

Pharmacotherapeutic group

  • Insulins

Special precautions for storage

In a place protected from light, at a temperature of 2-8 °C. Do not allow freezing.

Keep out of reach of children.

Shelf life of the drug Brinsulmidi H 40 units/ml2,5 года.

Do not use after the expiration date indicated on the package.

Nature and contents of container

1 ml of suspension for injection contains 40 units of human insulin zinc suspension, as well as methylparahydroxybenzoate, sodium acetate, sodium chloride, zinc acetate and water for injection, in glass bottles of 10 ml, in a cardboard pack of 1 bottle.

Nosological classification (ICD-10)

  • E14 Diabetes mellitus, unspecified

Dosage (Posology) and method of administration

N / a, 1-2 times a day, the dose is determined individually, before use, the bottle is gently shaken. The drug must be administered immediately after the set in the syringe. A daily dose exceeding 0.6 U / kg should be administered as two injections in different areas of the body.

ATC - Anatomical and therapeutic chemical classification

A10AC Medium-acting insulins and their analogues for injectable administration